WHEN YOU’RE SEARCHING FOR ANSWERS
BE CERTAIN WITH DISCERN™

Click here for patients. Click here for providers.

DISCERN FINAL LOGO HORIZONTAL.png

DISCERN™ is the world’s first easy to administer test that can accurately identify Alzheimer’s Disease even at the earliest stages of onset by testing for the presence of 3 key proprietary biomarkers, unique to AD. It enables healthcare providers a definitive diagnosis of AD versus other forms of dementia and empowers them to enact a plan of care and a pathway to prepare for the future.

Easily administered, DISCERN™ requires a small skin sample taken by a certified healthcare provider. DISCERN™ is the only test that can provide clinicians a diagnosis with 95% certainty whether a patient has Alzheimer’s Disease or not.

 
 
unsplash-image-VMGAbeeJTKo.jpg

Patients with a dementia diagnosis can use DISCERN™ to determine if they have Alzheimer’s Disease or not.

For Patients
Screen Shot 2021-03-16 at 10.37.48 AM.png

When having a test that gives 95% specificity and sensitivity provides physicians an amenable answer.

For Providers
Featured
The Cost Burdens of Diagnosing and Treating Alzheimer’s Disease: Alarming Issues for Patients, Providers and Payers Nationwide
The Cost Burdens of Diagnosing and Treating Alzheimer’s Disease: Alarming Issues for Patients, Providers and Payers Nationwide
Clinician Alert: Identify the Right Patients at the Right Time for Disease Modifying Therapies to Address Alzheimer’s Disease
Clinician Alert: Identify the Right Patients at the Right Time for Disease Modifying Therapies to Address Alzheimer’s Disease
Seven Ways to Care for Your Brain 
Seven Ways to Care for Your Brain 

Caring for your brain can prevent cognitive decline and neurodegenerative diseases such as Alzheimer’s disease (AD). Celebrate Brain Awareness Week by learning strategies to keep your brain healthy.

FDA Approves Alzheimer’s Agent Leqembi Shortly After Release of Congressional Aduhelm Report
FDA Approves Alzheimer’s Agent Leqembi Shortly After Release of Congressional Aduhelm Report
The Burden of Diagnosis: How physicians confront diagnosing Alzheimer’s disease with influx of patients seeking disease modifying therapies
The Burden of Diagnosis: How physicians confront diagnosing Alzheimer’s disease with influx of patients seeking disease modifying therapies
FDA Approval of New Drug for Alzheimer’s Disease Underscores Need for DISCERN™ Accurate Diagnostic Testing Prior to Prescribing LEQEMBI™ and Finalizing Coverage
FDA Approval of New Drug for Alzheimer’s Disease Underscores Need for DISCERN™ Accurate Diagnostic Testing Prior to Prescribing LEQEMBI™ and Finalizing Coverage
SYNAPS Dx DISCERN™: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years
SYNAPS Dx DISCERN™: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years

SYNAPS Dx Releases Positive Budget Impact Results for DISCERN™ at International Conference on Aging Diseases and Elderly Care: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years

SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN™ Test
SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERN™ Test
ISPOR Annual Conference: 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease
ISPOR Annual Conference: 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease
Semler Scientific Investment Advances Market Positioning and Confidence in SYNAPS Dx
Semler Scientific Investment Advances Market Positioning and Confidence in SYNAPS Dx

“We believe this investment continues to distinguish the accuracy of our biomarkers from all other diagnostics in Alzheimer’s Disease, since it is undoubtedly the first accurate, gold-standard autopsy-confirmed minimally invasive test for the definitive diagnosis of AD vs. other forms of dementia,” says Frank Amato, CEO and president, SDx. “DISCERN relies on three independently accurate biomarkers related to synaptic function and is well positioned to help address a number of key issues that payers, providers and patients face when it comes to getting a definitive diagnosis for AD early in the patient journey.”